Rectal Microbicides: The Basics. Date, Location Your name, Your affiliation

Similar documents
Rectal Microbicides: The Basics. 6 July 2010 Amsterdam Marc-André LeBlanc, IRMA Secretary

On the Horizon for Consideration: Biomedical Advances in HIV Prevention

Program to control HIV/AIDS

South African Guidelines for the Safe Use of. Dr. Oscar Radebe

Less Silence, More Science Advocacy to Make Rectal Microbicides a Reality Jim Pickett Chair, IRMA. Rectal Microbicides Update 24 February 2008

Multiple choice questions: ANSWERS

Combination HIV Prevention

ViiV Healthcare s Position on Prevention in HIV

The Big Picture: The current and evolving HIV prevention landscape

International Partnership for Microbicides. Microbicides: New HIV Protection for Women Global Diseases: Voices from the Vanguard

Towards universal access

Viva La Rectum! Revolutionizing Sex in the New Millennium LGBTI Health Summit 2007 Philadelphia

In July 2011, FHI became FHI 360.

ART for prevention the task ahead

ETHICS IN HIV PREVENTION RESEARCH IN THE NEW ERA OF

Colloque scientifique : L économie de la prévention Analysis of Cost-Effectiveness of HIV Prevention

Biomedical Prevention in HIV

Government of Canada Federal AIDS Initiative Milestones

HIV Resource Allocations using AEM

Update on ARV based PrEP

HIV and the Buckeye State

Emerging HIV Prevention Technologies and Canada s African, Caribbean and Black Communities PURPOSE. The science of HIV prevention is advancing quickly

Microbicides: User-controlled HIV prevention

Engaging African Men in Rectal Microbicides BRIAN KANYEMBA RESEARCH ASSISTANT

ACCELERATING HIV COMBINATION PREVENTION HIV COMBINATION PREVENTION INTERVENTIONS

I M ENDING HIV PATIENT INFORMATION. endinghiv.org.au/prep

HIV AND AIDS FACT SHEETS

Services and Support Information Leaflet

Linkages between Sexual and Reproductive Health and HIV

Update on PrEP progress: WHO/UNAIDS challenges and actions

PrEP for Women. Together, we can change the course of the HIV epidemic one woman at a time.

2020 Vision: making England s HIV prevention response the best in the world

Health Promotion Service Project Overview

REPORT OF THE EXECUTIVEDIRECTOR

Strategic use of antiretroviral drugs to prevent HIV transmission

The Need for Parallel Development of Rectal Microbicides

International Partnership for Microbicides

Development of Rectal Microbicides

Prevention targets & scorecard

Treatment Trends for South African MSM. Kevin Rebe

HIV / AIDS. Prevention In Our Lives

amfar Funding for rectal HIV transmission and microbicides research Rowena Johnston, Ph.D.

FPA Sri Lanka Policy: Men and Sexual and Reproductive Health

The HIV Prevention England programme: what s next? Cary James May 2016

Emma Zurowski PaSH Programme Lead BHA for Equality. Peter Bampton Sexual Health Lead LGBT Foundation. gmpash.org.uk.

Prevention and care towards vulnerable and stigmatized populations (MSM, drug users, sex workers)

FAST-TRACK COMMITMENTS TO END AIDS BY 2030

Using anti-hiv drugs for prevention

Groups of young people in Uganda that need to be targeted with HIV interventions

EVALUATION TOOLS...123

Understanding the Results of VOICE

South Africa s National HIV Programme. Dr Zuki Pinini HIV and AIDS and STIs Cluster NDOH. 23 October 2018

Policy Overview and Status of the AIDS Epidemic in Zambia

Translating Science to end HIV in Latin America and the Caribbean

BUDGET AND RESOURCE ALLOCATION MATRIX

FAST-TRACK: HIV Prevention, treatment and care to End the AIDS epidemic in Lesotho by 2030

If you are a man that ONLY has sex with women this may not be the brochure for you.

Regional Administration Officer Te Toka Centre JOB DESCRIPTION

Promoting the health and wellbeing of gay, bisexual and other men who have sex with men. Summary Document

COMMUNITY SYSTEMS TOOLBOX COMMUNITY SYSTEMS STRENGTHENING. Increasing access to quality health and social services. Building strong communities.

ASEAN Declaration of Commitment on HIV and AIDS: Fast-Tracking and Sustaining HIV and AIDS Responses To End the AIDS Epidemic by 2030

From choice, a world of possibilities. Strategic framework

HIV PREVENTION, DIAGNOSIS, TREATMENT AND CARE FOR KEY POPULATIONS

Thresia Sebastian MD, MPH University of Colorado, Denver Global Health Disasters Course October 2016

AN ACTIVITY-BASED COSTING TOOL

Combination HIV Prevention Research Carl W. Dieffenbach, Ph.D.

Antiretroviral Drugs for HIV Seronegative People: It works in trials, what about the real world?

Doing studies of ARV based

HIV/SRHR Integration for People Living with HIV

Lubrication. What?! Why?! But our sexual health is not private! thoughts and discussions

The Latest on HIV Testing. Dominika Seidman, MD MAS

A Daily Pill to Prevent HIV: Oral Pre-exposure Prophylaxis (PrEP)

Get Informed! HIV Quick Facts You need to understand the issues before you can make a difference.

HIV Vaccine Clinical Trials at CIDRZ

Pre-Exposure Topical Microbicides and Oral Prophylaxis Trials:

PRECONCEPTION COUNSELING

IFMSA Policy Statement Ending AIDS by 2030

Health Initiative for Men. strengthening the health and well-being of gay men

ONLY IN HUMANS! CAN GET SICK FASTER. What is HIV? NO CURE. Human Immunodeficiency Virus. HIV ATTACKS your T-cells. And uses them to of itself

Improving outcomes The UK s achievements in managing and preventing the HIV epidemic and how we should approach public health priorities

Effective HIV & AIDS prevention strategies

Concept paper on the guidance on the non-clinical and clinical development of medicinal products for HIV prevention including oral and topical PrEP

Arizona State Office of Rural Health Webinar Series

Understanding HIV/AIDS: The current state of the HIV epidemic in British Columbia Mark Gilbert, MD, MHSc, FRCPC

Direct from Delhi: Microbicides2008 Comes to Sweet Home Chicago

QUESTIONS AND ANSWERS ABOUT PARTNERS PrEP AND VOICE

Fertility Desires/Management of Serodiscordant HIV + Couples

Item 4. Sexual Health and Blood Borne Virus Strategy Strategy for Sexual Health and Blood Borne Viruses. Background

Biomedical HIV Prevention & PrEP Pre exposure Prophylaxis 2013

AIDS. health concern. As of 2005, a cure for HIV/AIDS remains to be found. While medical

HIV: Pregnancy in Serodiscordant Couple. Dr Chow TS ID Clinic HPP

UNGASS Declaration of Commitment on HIV/AIDS: Core Indicators revision

STI and HIV Prevention and Care among Sex Workers

PrEP Home Checklist v1.0

PrEP: Pre Exposure Prophylaxis

PLANNING INTEGRATED HIV SERVICES AT THE HEALTH CENTRE

Providing Good Care to People Living with HIV

Renewing Momentum in the fight against HIV/AIDS

ART and Prevention: What do we know?

What s in the Biomedical Prevention Pipeline

Transcription:

Rectal Microbicides: The Basics Date, Location Your name, Your affiliation

This presentation Who is IRMA? Overview of the HIV epidemic New prevention technologies What are microbicides? Why do we need microbicides? Rectal microbicide research the basics IRMA goals and objectives Rectal microbicide advocacy and you

IRMA is Mission: support development of safe, effective, acceptable, and accessible rectal microbicides for all that need them Secretariat A global network of advocates, leading scientists, funders and policymakers from six continents w/chapters in Peru and Nigeria

Advocacy goals Updated Research snapshot Report includes: Global context Updated resource tracking & funding projections Overview IRMA activities

Global context

This presentation

Condoms work. So why do we need new strategies to halt the sexual transmission of HIV?

Here are some reasons for new strategies Source: Roger Tatoud PhD, Senior Programme Manager, International HIV Clinical Trials Research Mgmt Office, Imperial College London & IRMA Steering Committee Member

And here are some more Source: Measure Evaluation. 1997 2002. http://www.measuredhs.com

New Prevention Technologies

What if we had a complete prevention tool kit? Prior to exposure Point of transmission Treatment Rights-focused behaviour change Voluntary counselling and testing STI screening and treatment Male medical circumcision Preventive Vaccines Pre-exposure prophylaxis (PrEP) Male and female condoms and lube ARV treatment to prevent vertical transmission (PMTCT) Clean injecting equipment Post-exposure prophylaxis (PEP) Vaginal and rectal microbicides Improved ARV therapy Treatment for opportunistic infections Basic care/nutrition Prevention for positives Education & rights-focused behaviour change Therapeutic vaccines ARV = antiretroviral

What is a microbicide? A product applied topically in the vagina or the rectum that can offer protection against HIV and, ideally, other STI pathogens Ideally would have a contraceptive version, and another to allow for pregnancy Formulated as a lubricant, gel, film, or vaginal ring A rectal microbicide (RM) might be delivered via suppository, douche, or an enema in addition to a lube Microbicides are still in development they are not available yet!

How would a microbicide work? Non-ARV-based Prevents HIV from entering healthy cells by creating a barrier between the cell and HIV ARV-based Blocks specific proteins of HIV so that it cannot bind with a healthy cell In the case of a vaginal microbicide, could enhance the vagina s natural defense system Kills the virus by attacking it Blocks receptors on healthy cells so that HIV cannot bind with them Deactivates key components of the HIV to inhibit replication

Comparing ARV-based and non-arv-based microbicides ARV-based Non-ARV-based Advantages More potent against HIV May be long lasting Not contraceptive Could work against HIV and other STIs Could be contraceptive Disadvantages May be more toxic May cause resistance Unlikely to protect against other STIs May be less potent against HIV May need to be used at time of sex Source: Global Campaign for Microbicides

Gel, lubricant Vaginal ring Suppository Rectal Applicator Film Enema Examples of how a microbicide might be delivered

Microbicides the big picture Source: Roger Tatoud PhD, Senior Programme Manager, International HIV Clinical Trials Research Mgmt Office, Imperial College London & IRMA Steering Committee Member

Anal Intercourse

Anal intercourse is a human behaviour.

Anal intercourse and women In absolute numbers, 7x more heterosexual women than gay men and MSM in the US practice receptive anal intercourse (AI) - a conservative estimate [Halperin DT.] Prevalence of AI among heterosexuals is not well defined Varies regionally by age, population, co-risk AI is relatively common globally, 5 10% in gen. pop. and up to 30-50% of women with other HIV risks engage in AI Unprotected AI may be a significant source of HIV transmission in many contexts, including those labelled as heterosexual epidemics.

Anal Intercourse Gay men and other men who have sex with men (MSM) Anal intercourse is a common behaviour Most HIV infections due to unprotected AI Globally, MSM are 19x more likely to be infected with HIV than general population In North America, Western Europe, Latin America : Gay men and MSM make up most HIV infections In many African, Asian and Latin American countries: HIV among MSM significantly higher than general population Globally, only 9% of MSM in 2006 received any type of prevention

Challenges in rectal microbicide development Compared to microbicides for vaginal use, rectal microbicides are in much earlier stages of development because of: Political and cultural reluctance to address anal sex among gay men, MSM and between women and men Stigma Denial Homophobia Lack of understanding of need Scientific and biological challenges More complex safety issues rectum very fragile Lack of adequate resources

Biological challenges Vagina Most of the epithelium is 40 cell layers thick Fewer CD4 cells than rectum Rectum Very fragile epithelium, 1 cell layer thick More inflammatory cells under surface (CD4 receptors) Acidic ph Alkaline, rather than acidic ph Enclosed pouch Open-ended tube

Anatomy 101

The anus and rectum Source: Johns Hopkins Medicine

An act of unprotected anal intercourse is 10 to 20 times more likely to result in HIV transmission than an act of unprotected vaginal intercourse.

Science

Clinical trials Phase I safety Phase III efficacy, large scale Phase II expanded safety Phase IIb proof of concept

The Product Pipeline 3 in large-scale efficacy trials human safety trials pre-clinical testing early-stage concepts Source: Alliance for Microbicide Development, with thanks to Anna Forbes

Research activities Pre-clinical/basic science developing and testing products in labs and in animal studies Clinical trials safety and efficacy Are these RMs safe? Do they work? Acceptability & behavioural studies What kinds of products would people use? Who is having AI?

Research activities Baseline studies What normally happens during AI? Formulation studies How will different chemicals and substances be put together to make a safe, effective RM? Distribution studies Where do RMs need to go?

Research activities Source: From Promise to Product: Advancing Rectal Microbicide Research and Advocacy

Advocacy, Funding, IRMA and You

Advocacy goals Increase and diversify funding Increase research activities Increase knowledge o o - For instance: Learn more about heterosexual anal sex Lear more about anal sex behaviours and practices in general

Advocacy goals Increase and diversify funding Source: From Promise to Product: Advancing Rectal Microbicide Research and Advocacy

Advocacy goals Projected funding needs Source: From Promise to Product: Advancing Rectal Microbicide Research and Advocacy

Advocacy goals Develop Global Rectal Microbicide Development Plan Every R&D dollar/euro needs to be spent smartly and strategically Find consensus on research priorities among stakeholders Coordinate research activities, from discovery through Phase III Monitor progress

Advocacy goals Recruit researchers, advocates Recognise anal intercourse as an important driver in the HIV epidemic among gay men, MSM, and heterosexuals Address burden of HIV among gay men and MSM particularly in the developing world Promote anal health Determine safety of lubricants for rectal use http://tinyurl.com/lube-studies

What can you do?

What you can do in 5 minutes Join IRMA - sign up for IRMA listserv through website Read one fact sheet or news item from website or blog Join us on Facebook and Twitter Share web address and contact information w/another advocate, researcher, policy maker, potential funder irma-alc.blogspot.com www.rectalmicrobicides.org

What you can do in 30-60 minutes Join one of IRMA s regular free teleconferences featuring world leaders in RM research, advocacy Read From Promise to Product: Advancing Rectal Microbicide Research and Advocacy or read one of the presentations from researchers, community members Talk to members of your community about your interest in rectal microbicides

Want to do more? Become your community s rectal microbicide expert and spokesperson Recruit new members, enlist organisational support for RMs Conduct presentations in your community use this one as a template! Write an article, a blog or a Facebook update on RMs - IRMA will help!

Want to do more? Join one of IRMA s working groups Lubricant Safety European Outreach Communications Fundraising Connect with IRMA ALC, IRMA Nigeria irma-alc.blogspot.com

Special thanks to IRMA funders

Questions?

Thank you Your name Your affiliation Your email address irma-alc.blogspot.com rectalmicrobicides.org